What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 10, 2016, Pages 875-878

  Gentile, Ivan ^a   Maraolo, Alberto Enrico ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

carbapenem sparing regimens; ceftazidime avibactam; Ceftolozane tazobactam; complicated intra abdominal infections; complicated urinary tract infections; Enterobacteriaceae; multidrug resistance; Pseudomonas aeruginosa

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; MEROPENEM; METRONIDAZOLE; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAM; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLINICAL TRIAL (TOPIC); CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDITORIAL; ENTEROBACTERIACEAE; EVIDENCE BASED MEDICINE; GRAM NEGATIVE INFECTION; HUMAN; KIDNEY FAILURE; MEDICATION THERAPY MANAGEMENT; MONTE CARLO METHOD; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ENTEROBACTERIACEAE INFECTION; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; CEFTAZIDIME; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INTRAABDOMINAL INFECTIONS; PENICILLANIC ACID; PSEUDOMONAS INFECTIONS; URINARY TRACT INFECTIONS;

EID: 84987762164     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1080/14787210.2016.1233060     Document Type: Editorial

References (44)

1. R.Laxminarayan, P.Matsoso, S.Pant, et al. Access to effective antimicrobials:a worldwide challenge. Lancet. 2016;387:168–175.
2. Centers for Diseases Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. [cited 2016 July 15] Available from:http://www.cdc.gov/drugresistance/threat-report-2013/.•• The most recent overview on antibiotic resistance threats in the United States.
3. J.Iredell, J.Brown, K.Tagg Antibiotic resistance in Enterobacteriaceae:mechanisms and clinical implications. Bmj. 2016;352:h6420.
4. M.Chatterjee, C.P.Anju, L.Biswas, et al. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int J Med Microbiol. 2016;306:48–58.
5. D.van Duin, R.A.Bonomo. Ceftazidime/avibactam and ceftolozane/tazobactam:second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–241.•• A comprehensive review about the current clinical indications for ceftolozane/tazobactam and ceftazidime/avibactam.
6. T.F.Barlam, S.E.Cosgrove, L.M.Abbo, et al. Implementing an antibiotic stewardship program:guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51–77.
7. J.L.Liscio, M.V.Mahoney, E.B.Hirsch. Ceftolozane/tazobactam and ceftazidime/avibactam:two novel beta-lactam/beta-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015;46:266–271.
8. K.M.Papp-Wallace, R.A.Bonomo. New beta-lactamase inhibitors in the clinic. Infect Dis Clin North Am. 2016;30:441–464.
9. P.N.Harris, P.A.Tambyah, D.L.Paterson. beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae:time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15:475–485.
10. M.McLaughlin, M.R.Advincula, M.Malczynski, et al. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57:5131–5133.
11. P.Viale, M.Giannella, S.Tedeschi, et al. Treatment of MDR-Gram negative infections in the 21st century:a never ending threat for clinicians. Curr Opin Pharmacol. 2015;24:30–37.
12. S.M.Drawz, K.M.Papp-Wallace, R.A.Bonomo. New beta-lactamase inhibitors:a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58:1835–1846.
13. B.Moya, L.Zamorano, C.Juan, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54:3933–3937.
14. L.J.Scott. Ceftolozane/tazobactam:a review in complicated intra-abdominal and urinary tract infections. Drugs. 2016;76:231–242.
15. H.S.Sader, D.J.Farrell, R.K.Flamm, et al. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals:results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents. 2014;43:328–334.
16. D.Cluck, P.Lewis, B.Stayer, et al. Ceftolozane-tazobactam:a new-generation cephalosporin. Am J Health Syst Pharm. 2015;72:2135–2146.
17. J.A.Karlowsky, D.J.Biedenbach, K.M.Kazmierczak, et al. Activity of ceftazidime-avibactam against extended-spectrum- and AmpC β-lactamase-producing Enterobacteriaceae collected in the INFORM Global Surveillance Study from 2012 to 2014. Antimicrob Agents Chemother. 2016;60:2849–2857.
18. E.J.Zasowski, J.M.Rybak, M.J.Rybak. The beta-lactams strike back:ceftazidime-avibactam. Pharmacotherapy. 2015;35:755–770.
19. G.G.Zhanel, C.D.Lawson, H.Adam, et al. Ceftazidime-avibactam:a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73:159–177.• A detailed description of the main features of ceftazidime/avibactam.
20. S.D.Lahiri, S.Mangani, T.Durand-Reville, et al. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism:avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob Agents Chemother. 2013;57:2496–2505.
21. G.G.Zhanel, P.Chung, H.Adam, et al. Ceftolozane/tazobactam:a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74:31–51.• A thorough article addressing all the pharmacological aspects of ceftozolane/tazobactam.
22. R.Sharma, T.Eun Park, S.Moy. Ceftazidime-avibactam:a novel cephalosporin/beta-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther. 2016;38:431–444.
23. K.Bush. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46:483–493.
24. F.M.Wagenlehner, O.Umeh, J.Steenbergen, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis:a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–1956.
25. J.A.Vazquez, L.D.Gonzalez Patzan, D.Stricklin, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults:results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921–1931.
26. J.A.Huntington, G.Sakoulas, O.Umeh, et al. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens:results from the ASPECT-cUTI trial. J Antimicrob Chemother. 2016;71:2014–2021.
27. J.Solomkin, E.Hershberger, B.Miller, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance:results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–1471.
28. C.Lucasti, I.Popescu, M.K.Ramesh, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults:results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68:1183–1192.
29. J.E.Mazuski, L.B.Gasink, J.Armstrong, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection:results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380–1389.
30. Y.Carmeli, J.Armstrong, P.J.Laud, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE):a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–673.
31. J.Rodriguez-Bano. The times they are a-changin’:carbapenems for extended-spectrum-beta-lactamase-producing bacteria. Antimicrob Agents Chemother. 2015;59:5095–5096.
32. T.P.Van Boeckel, S.Gandra, A.Ashok, et al. Global antibiotic consumption 2000 to 2010:an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14:742–750.
33. P.Nordmann, T.Naas, L.Poirel. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–1798.
34. G.Borgia, A.E.Maraolo, M.Foggia, et al. Fecal microbiota transplantation for Clostridium difficile infection:back to the future. Expert Opin Biol Ther. 2015;15:1001–1014.
35. X.Wang, F.Zhang, C.Zhao, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 Gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58:1774–1778.
36. F.Perez, N.G.El Chakhtoura, K.M.Papp-Wallace, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae:can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17:761–781.
37. S.E.Giancola, M.V.Mahoney, T.E.Bias, et al. Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections. Ther Clin Risk Manag. 2016;12:787–797.
38. P.Viale, M.Giannella, M.Bartoletti, et al. Considerations about antimicrobial stewardship in settings with epidemic extended-spectrum beta-lactamase-producing or carbapenem-resistant Enterobacteriaceae. Infect Dis Ther. 2015;4(Suppl 1):65–83.
39. A.Liapikou, A.Torres. Emerging drugs for nosocomial pneumonia. Expert Opin Emerg Drugs. 2016;7:1–11.
40. M.S.Gelfand, K.O.Cleveland. Ceftolozane/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015;61:853–855.
41. A.J.Xiao, B.W.Miller, J.A.Huntington, et al. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66.
42. P.Lagace-Wiens, A.Walkty, J.A.Karlowsky. Ceftazidime-avibactam:an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13–25.
43. J.F.Camargo, J.Simkins, T.Beduschi, et al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2015;59:5903–5098.
44. S.M.Tamma, A.J.Hsu, P.D.Tamma. Prescribing ceftolozane/tazobactam for pediatric patients:current status and future implications. Paediatr Drugs. 2016;18:1–11.